Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

– Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute – No adverse reactions observed, and study can continue as planned EDMONTON, Alberta, Dec. 13, 2023 --  Ceapro...

Related Keywords

Montreal ,Quebec ,Canada ,Canadian ,Jenene Thomas ,Paul David ,Gilles Gagnon ,Jean Claude Tardif ,Montreal Health Innovations Coordinating Center ,Corporate Communications Advisor ,Montreal Heart Institute ,Ceapro Inc ,Montreal Heart ,Corporate Communications ,Markets ,